Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis-Reference-Cited by-同舟云学术

Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis

Published:2018-02-24 Issue:5 Volume:93 Page:649-654
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am J Hematol

Author:

Tefferi Ayalew¹^ORCID,Partain Daniel K.¹,Palmer Jeanne M.²,Slack James L.²,Roy Vivek³,Hogan William J.¹,Litzow Mark L.¹,Ketterling Rhett P.⁴,Patnaik Mrinal M.¹^ORCID

Affiliation:

1. Divisions of Hematology; Mayo Clinic; Rochester Minnesota

2. Division of Hematology and Medical Oncology, Department of Medicine; Mayo Clinic; Phoenix Arizona

3. Division of Hematology-Oncology; Mayo Clinic; Jacksonville Florida

4. Laboratory Genetics and Genomics, Departments of Internal Medicine and Laboratory Medicine; Mayo Clinic; Rochester Minnesota

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.25053/fullpdf

Reference24 articles.

1. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management;Tefferi;Am J Hematol.,2016

2. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients;Polverelli;Am J Hematol.,2017

3. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group;Kroger;Leukemia.,2015

4. Allogeneic hematopoietic stem cell transplantation for myelofibrosis and chronic myelomonocytic leukemia;Kekre;Am J Hematol.,2016

5. Myeloproliferative neoplasms: a decade of discoveries and treatment advances;Tefferi;Am J Hematol.,2016

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk models in myelofibrosis—the past, present, and future;American Journal of Hematology;2024-02-23

2. How I treat transplant-eligible patients with myelofibrosis;Blood;2023-11-16

3. Adoptive Immunotherapy via Donor Lymphocyte Infusions following Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Real-World, Retrospective Multicenter Study;Transplantation and Cellular Therapy;2023-11

4. CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant;Bone Marrow Transplantation;2023-10-11

5. Ruxolitinib: a new first-line strategy in autoimmune myelofibrosis treatment;Leukemia & Lymphoma;2023-07-13